FDA expands sevabertinib approval in NSCLC - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA expands sevabertinib approval in NSCLC

SOHO-01 data showed a 75% confirmed objective response rate among 69 patients without previous systemic therapy.

  • By

  • Kathryn Wighton

  • September 9, 2026

  • 2 min

Share

Original Source(s)

FDA expands sevabertinib approval in NSCLC

  • by Kathryn Wighton

  • September 9, 2026

Related Content

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

“There is incredible uncertainty in drug dosing.”

Case Report: Delayed appearance of the ablation margin after CT-guided microwave ablation of a solid pulmonary nodule